

1.

Abraham H. The Psychopharmacology of Hallucinogens. *Neuropsychopharmacology*. 1996 Apr;14(4):285–98.

2.

Berkowitz E, River Y, Digre K, Tiosano B, Kesler A. Visual Snow: A Case Series from Israel. *Case Rep Ophthalmol*. 2020 Jun 9;11(2):205–11.

3.

Bersani FS, Corazza O, Albano G, Valeriani G, Santacroce R, Bolzan Mariotti Posocco F, et al. 25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug. *BioMed Research International*. 2014;2014:1–6.

4.

Charre M, Herrero H, Martelli C, Benyamina A. Syndrome post-hallucinogène persistant : discussion à propos d'une situation clinique. *L'Encéphale*. 2020 Oct;46(5):408–9.

5.

Cinosi E, Corazza O, Santacroce R, Lupi M, Acciavatti T, Martinotti G, et al. New Drugs on the Internet: The Case of Camfetamine. *BioMed Research International*. 2014;2014:1–8.

6.

Corazza O, Valeriani G, Bersani FS, Corkery J, Martinotti G, Bersani G, et al. “Spice,” “Kryptonite,” “Black Mamba”: An Overview of Brand Names and Marketing Strategies of Novel Psychoactive Substances on the Web. *Journal of Psychoactive Drugs*. 2014 Aug 8;46(4):287–94.

7.

Cudeiro J, Sillito AM. Looking back: corticothalamic feedback and early visual processing. *Trends in Neurosciences*. 2006 Jun;29(6):298–306.

8.

Fantini J, Sartori A, Manganotti P. Can We Speak of Lack of Habituation in Visual Snow? *Headache*. 2016 Oct;56(9):1517–8.

9.

- Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. *Experimental and Clinical Psychopharmacology*. 2016 Aug;24(4):229–68. 10.
- Guillery RW, Sherman SM. Thalamic Relay Functions and Their Role in Corticocortical Communication. *Neuron*. 2002 Jan;33(2):163–75. 11.
- Hermle L, Ruchow M, Täschner K. Halluzinogen-induzierte Persistierende Wahrnehmungsstörung (HPPD) und Flashback-Phänomene – Differenzialdiagnose und Erklärungsmodelle. *Fortschr Neurol Psychiatr*. 2015 Sep 30;83(09):506–15. 12.
- Hermle L, Simon M, Ruchow M, Geppert M. Hallucinogen-persisting perception disorder. *Therapeutic Advances in Psychopharmacology*. 2012 Oct;2(5):199–205. 13.
- Hodak J, Fischer U, Bassetti CLA, Schankin CJ. Episodic Visual Snow Associated With Migraine Attacks. *JAMA Neurol*. 2020 Mar 1;77(3):392. 14.
- Kurtom M, Henning A, Espiridion ED. Hallucinogen-persisting Perception Disorder in a 21-year-old Man. *Cureus* [Internet]. 2019 Feb 14 [cited 2023 Jan 1]; Available from: <https://www.cureus.com/articles/16869-hallucinogen-persisting-perception-disorder-in-a-21-year-old-man> 15.
- Martinotti G, Lupi M, Acciavatti T, Cinosi E, Santacroce R, Signorelli MS, et al. Novel Psychoactive Substances in Young Adults with and without Psychiatric Comorbidities. *BioMed Research International*. 2014;2014:1–7. 16.
- Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano M, Lorusso M, et al. Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. *Brain Sciences*. 2018 Mar 16;8(3):47. 17.

- McKendrick AM, Chan YM, Tien M, Millist L, Clough M, Mack H, et al. Behavioral measures of cortical hyperexcitability assessed in people who experience visual snow. *Neurology*. 2017 Mar 28;88(13):1243–9. 18.
- Noushad F. 25 years of Hallucinogen Persisting Perception Disorder- A diagnostic challenge. 2015;8(1). 19.
- Orsolini L, Francesconi G, Papanti D, Giorgetti A, Schifano F. Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces: Profiling the online drugs' consumers. *Hum Psychopharmacol Clin Exp*. 2015 Jul;30(4):302–18. 20.
- Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F. The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. *Front Psychiatry*. 2017 Nov 20;8:240. 21.
- Puledda F, Ffytche D, Lythgoe DJ, O'Daly O, Schankin C, Williams SCR, et al. Insular and occipital changes in visual snow syndrome: a BOLD fMRI and MRS study. *Ann Clin Transl Neurol*. 2020 Mar;7(3):296–306. 22.
- Puledda F, Schankin C, Goadsby PJ. Visual snow syndrome: A clinical and phenotypical description of 1,100 cases. *Neurology*. 2020 Feb 11;94(6):e564–74. 23.
- Renze M. Visual Snow Syndrome and Its Relationship to Tinnitus. *The International Tinnitus Journal* [Internet]. 2017 [cited 2023 Jan 1];21(1). Available from: <http://www.gnresearch.org/doi/10.5935/0946-5448.20170014> 24.
- Schankin CJ, Maniyar FH, Chou DE, Eller M, Sprenger T, Goadsby PJ. Structural and functional footprint of visual snow syndrome. *Brain*. 2020 Apr 1;143(4):1106–13. 25.
- Schankin CJ, Maniyar FH, Digre KB, Goadsby PJ. ‘Visual snow’ – a disorder distinct from persistent migraine aura. *Brain*. 2014 May;137(5):1419–28.

- 26.
- Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Novel psychoactive substances of interest for psychiatry. *World Psychiatry*. 2015 Feb;14(1):15–26.
- 27.
- Traber GL, Piccirelli M, Michels L. Visual snow syndrome: a review on diagnosis, pathophysiology, and treatment. *Current Opinion in Neurology*. 2020 Feb;33(1):74–8.
- 28.
- van Dongen RM, Waaijer LC, Onderwater GLJ, Ferrari MD, Terwindt GM. Treatment effects and comorbid diseases in 58 patients with visual snow. *Neurology*. 2019 Jul 23;93(4):e398–403.
- 29.
- Walsh CA, Livne O, Shmulewitz D, Stohl M, Hasin DS. Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002–2019. *Addictive Behaviors Reports*. 2022 Dec;16:100454.
- 30.
- Walsh CA, Livne O, Shmulewitz D, Stohl M, Hasin DS. Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002–2019. *Addictive Behaviors Reports*. 2022 Dec;16:100454.
- 31.
- Xu X, Ichida JM, Allison JD, Boyd JD, Bonds AB, Casagrande VA. A comparison of koniocellular, magnocellular and parvocellular receptive field properties in the lateral geniculate nucleus of the owl monkey (*Aotus trivirgatus*). *The Journal of Physiology*. 2001 Feb;531(1):203–18.
- 32.
- Zhou K, De Wied D, Carhart-Harris R, Kettner H. Predictors Of Hallucinogen Persisting Perception Disorder Symptoms, Delusional Ideation And Magical Thinking Following Naturalistic Psychedelic Use [Internet]. *PsyArXiv*; 2022 Nov [cited 2023 Jan 1]. Available from: <https://osf.io/txzha>
- 33.
- Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings.
- 34.

- Abraham, Henry D. When the trip doesn't end [Internet]. BPS. [cited 2023 Jan 1]. Available from: <https://www.bps.org.uk/volume-27/edition-9/when-trip-doesnt-end> 35.
- Mora V. Opinion/Editorial: Visual Snow Syndrome in the Women's Magazine, Cosmopolitan [Internet]. Visual Snow Initiative. 2022 [cited 2023 Jan 1]. Available from: <https://www.visualsnowinitiative.org/awarness/opinion-editorial-visual-snow-syndrome-in-the-womens-magazine-cosmopolitan/> 36.
- Woolfe, Sam. HPPD: What Is It, And What Are Its Symptoms? - HealingMaps [Internet]. [cited 2023 Jan 1]. Available from: <https://healingmaps.com/hppd-definition-symptoms/> 37.
- Visual Snow Initiative - Collaborate, Educate, and Cure [Internet]. [cited 2023 Jan 24]. Available from: <https://www.visualsnowinitiative.org/> 38.
- A G Lerner. Naltrexone treatment of hallucinogen persisting perception disorder. *AJP*. 1997 Mar 1;154(3):437a-437. 39.
- Abraham HD, Wolf E. Visual function in past users of LSD: Psychophysical findings. *Journal of Abnormal Psychology*. 1988 Nov;97(4):443-7. 40.
- Abraham HD. A Chronic Impairment of Colour Vision in Users of LSD. *Br J Psychiatry*. 1982 May;140(5):518-20. 41.
- Abraham HD. Visual Phenomenology of the LSD Flashback. *Arch Gen Psychiatry*. 1983 Aug 1;40(8):884. 42.
- Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. *Addiction*. 1993 Oct;88(10):1327-34.

43.

Abraham HD, Duffy FH. Stable quantitative EEG difference in post-LSD visual disorder by split-half analysis: evidence for disinhibition. *Psychiatry Research: Neuroimaging*. 1996 Oct;67(3):173–87.

44.

Abraham HD, Hopkins Duffy F. EEG coherence in post-LSD visual hallucinations. *Psychiatry Research: Neuroimaging*. 2001 Oct;107(3):151–63.

45.

Abraham HD, Mamen A. LSD-Like Panic From Risperidone in Post-LSD Visual Disorder: *Journal of Clinical Psychopharmacology*. 1996 Jun;16(3):238–41.

46.

Alcantara AG. Is There a Role for the [small alpha, Greek]2 Antagonism in the Exacerbation of Hallucinogen-Persisting Perception Disorder with Risperidone?: *Journal of Clinical Psychopharmacology*. 1998 Dec;18(6):487–8.

47.

Aldurra G, Crayton JW. Improvement of Hallucinogen-Induced Persistent Perception Disorder by Treatment With a Combination of Fluoxetine and Olanzapine: Case Report: *Journal of Clinical Psychopharmacology*. 2001 Jun;21(3):343–4.

48.

Asensio-Sánchez VM. Nieve visual. *Archivos de la Sociedad Española de Oftalmología*. 2018 Apr;93(4):e23–4.

49.

Berkowitz E, River Y, Tiosano B, Kesler A. [WHEN IT SNOWS ALL YEAR ROUND - VISUAL SNOW]. *Harefuah*. 2019 Jan;158(1):44–7.

50.

Bessero AC, Plant GT. Should “visual snow” and persistence of after-images be recognised as a new visual syndrome? *Journal of Neurology, Neurosurgery & Psychiatry*. 2014 Sep 1;85(9):1057–8.

51.

Beyer U, Gaul C. [Visual snow]. *Nervenarzt*. 2015 Dec;86(12):1561–5.

52.

Bou Ghannam A, Pelak VS. Visual Snow: a Potential Cortical Hyperexcitability Syndrome. *Curr Treat Options Neurol*. 2017 Mar;19(3):9.

53.

Brodrick J, Mitchell BG. Hallucinogen Persisting Perception Disorder and Risk of Suicide. *Journal of Pharmacy Practice*. 2016 Aug;29(4):431–4.

54.

Caton CLM, Drake RE, Hasin DS, Dominguez B, Shrout PE, Samet S, et al. Differences Between Early-Phase Primary Psychotic Disorders With Concurrent Substance Use and Substance-Induced Psychoses. *Arch Gen Psychiatry*. 2005 Feb 1;62(2):137.

55.

Chen BS, Lance S, Lallu B, Anderson NE. Visual snow: Not so benign. *Journal of Clinical Neuroscience*. 2019 Jun;64:37–9.

56.

Coppola M, Mondola R. JWH-122 Consumption Adverse Effects: A Case of Hallucinogen Persisting Perception Disorder Five-Year Follow-Up. *Journal of Psychoactive Drugs*. 2017 May 27;49(3):262–5.

57.

Costello FE, Bisdorff AR, Robbins MS. Visual snow: Are we beginning to see the light? *Neurology*. 2020 Feb 11;94(6):241–2.

58.

Daniels LK. Rapid in-office and in-vivo desensitization of an injection phobia utilizing hypnosis. *Am J Clin Hypn*. 1976 Jan;18(3):200–3.

59.

Domb, Sierra. What is Visual Snow? Transforming Anguish into Action | Sierra Domb | TEDxUMiami - YouTube [Internet]. [cited 2023 Jan 1]. Available from:
https://www.youtube.com/watch?v=rsyai3GGXjs&ab_channel=TEDxTalks

60.

- Ellison-Wright Z, Sessa B. A persisting perception disorder after cannabis use: Persisting perception disorder. *Prog Neurol Psychiatry*. 2015 Jan;19(1):10–3. 61.
- Eren OE, Ruscheweyh R, Straube A, Schankin CJ. Quantification of photophobia in visual snow syndrome: A case-control study. *Cephalalgia*. 2020 Apr;40(4):393–8. 62.
- Eren O, Rauschel V, Ruscheweyh R, Straube A, Schankin CJ. Evidence of dysfunction in the visual association cortex in visual snow syndrome: VEPs in Visual Snow. *Ann Neurol*. 2018 Dec;84(6):946–9. 63.
- Espiard ML, Lecardeur L, Abadie P, Halbecq I, Dollfus S. Hallucinogen persisting perception disorder after psilocybin consumption: a case study. *Eur psychiatr*. 2005 Aug;20(5–6):458–60. 64.
- G Lerner A, Goodman C, Bor O, Lev-Ran S. Synthetic Cannabis Substances (SPS) Use and Hallucinogen Persisting Perception Disorder (HPPD): Two Case Reports. *Isr J Psychiatry Relat Sci*. 2014;51(4):277–80. 65.
- G Lerner A, Goodman C, Rudinski D, Lev-Ran S. LSD Flashbacks - The Appearance of New Visual Imagery Not Experienced During Initial Intoxication: Two Case Reports. *Isr J Psychiatry Relat Sci*. 2014;51(4):307–9. 66.
- G Lerner A, Lev-Ran S. LSD-associated “Alice in Wonderland Syndrome”(AIWS): A Hallucinogen Persisting Perception Disorder (HPPD) Case Report. *Isr J Psychiatry Relat Sci*. 2015;52(1):67–8. 67.
- G Lerner A, Rudinski D, Bor O, Goodman C. Flashbacks and HPPD: A Clinical-oriented Concise Review. *Isr J Psychiatry Relat Sci*. 2014;51(4):296–301. 68.
- Garratt JC, Alreja M, Aghajanian GK. LSD has high efficacy relative to serotonin in enhancing the cationic current I_h: Intracellular studies in rat facial motoneurons. *Synapse*. 1993 Feb;13(2):123–34. 69.

- Grey V, Klobusiakova P, Minks E. Can repetitive transcranial magnetic stimulation of the visual cortex ameliorate the state of patients with visual snow? *BLL*. 2020;121(06):395–9. 70.
- Halpern J. Hallucinogen persisting perception disorder: what do we know after 50 years? *Drug and Alcohol Dependence*. 2003 Mar 1;69(2):109–19. 71.
- Halpern JH, Lerner AG, Passie T. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. In: Halberstadt AL, Vollenweider FX, Nichols DE, editors. *Behavioral Neurobiology of Psychedelic Drugs* [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2016 [cited 2023 Jan 1]. p. 333–60. (Current Topics in Behavioral Neurosciences; vol. 36). Available from: http://link.springer.com/10.1007/7854_2016_457 72.
- Halpern JH, Pope HG. Hallucinogens on the Internet: A Vast New Source of Underground Drug Information. *AJP*. 2001 Mar;158(3):481–3. 73.
- Hanck L, Schellekens AFA. [Hallucinogen persisting perception disorder after ecstasy use]. *Ned Tijdschr Geneeskd*. 2013;157(24):A5649. 74.
- Hofmann A. *LSD, my problem child*. New York: McGraw-Hill; 1980. 209 p. 75.
- Inaba D, Cohen WE. *Uppers, downers, all arounders: physical and mental effects of psychoactive drugs*. 7th ed. Ashland, Or: CNS Publications; 2011. 1 p. 76.
- Kilpatrick ZP, Bard Ermentrout G. Hallucinogen persisting perception disorder in neuronal networks with adaptation. *J Comput Neurosci*. 2012 Feb;32(1):25–53. 77.

- Knuijver T, Belgers M, Markus W, Verkes RJ, van Oosteren T, Schellekens A. Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence. *J Clin Psychopharmacol*. 2018 Dec;38(6):646–8. 78.
- Kondziella D, Olsen MH, Dreier JP. Prevalence of visual snow syndrome in the UK. *Eur J Neurol*. 2020 May;27(5):764–72. 79.
- Lauschke JL, Plant GT, Fraser CL. Visual snow: A thalamocortical dysrhythmia of the visual pathway? *Journal of Clinical Neuroscience*. 2016 Jun;28:123–7. 80.
- Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M, et al. LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study. *International Clinical Psychopharmacology*. 2000 Jan;15(1):35–7. 81.
- Lerner AG, Skladman I, Kodesh A, Sigal M, Shufman E. LSD-induced Hallucinogen Persisting Perception Disorder treated with clonazepam: two case reports. *Isr J Psychiatry Relat Sci*. 2001;38(2):133–6. 82.
- Lerner AG, Finkel B, Oyffe I, Merenzon I, Sigal M. Clonidine Treatment for Hallucinogen Persisting Perception Disorder. *AJP*. 1998 Oct;155(10):1460–1460. 83.
- Lerner AG, Gelkopf M, Skladman I, Oyffe I, Finkel B, Sigal M, et al. Flashback and Hallucinogen Persisting Perception Disorder: clinical aspects and pharmacological treatment approach. *Isr J Psychiatry Relat Sci*. 2002;39(2):92–9. 84.
- Lerner AG, Gelkopf M, Skladman I, Rudinski D, Nachshon H, Bleich A. Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. *International Clinical Psychopharmacology*. 2003 Mar;18(2):101–5. 85.

- Lerner AG, Goodman C, Rudinski D, Bleich A. Benign and time-limited visual disturbances (flashbacks) in recent abstinent high-potency heavy cannabis smokers: a case series study. *Isr J Psychiatry Relat Sci.* 2011;48(1):25–9. 86.
- Lerner AG, Shufman E, Kodesh A, Kretzmer G, Sigal M. LSD-induced Hallucinogen Persisting Perception Disorder with depressive features treated with reboxetine: case report. *Isr J Psychiatry Relat Sci.* 2002;39(2):100–3. 87.
- Lev-Ran S, Feingold D, Frenkel A, Lerner AG. Clinical Characteristics of Individuals With Schizophrenia and Hallucinogen Persisting Perception Disorder: A Preliminary Investigation. *Journal of Dual Diagnosis.* 2014 Apr 3;10(2):79–83. 88.
- Lev-Ran S, Feingold D, Goodman C, Lerner AG. Comparing triggers to visual disturbances among individuals with positive vs negative experiences of hallucinogen-persisting perception disorder (HPPD) following LSD use: Comparing Triggers to HPPD Type I and II. *Am J Addict.* 2017 Sep;26(6):568–71. 89.
- Lev-Ran S, Feingold D, Rudinski D, Katz S, Arturo LG. Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation. *Am J Addict.* 2015 Apr;24(3):197–9. 90.
- Litjens RPW, Brunt TM, Alderliefste GJ, Westerink RHS. Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases. *European Neuropsychopharmacology.* 2014 Aug;24(8):1309–23. 91.
- Martinotti G, Lupi M, Carlucci L, Cinosi E, Santacroce R, Acciavatti T, et al. Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas: NPS use and Knowledge. *Hum Psychopharmacol Clin Exp.* 2015 Jul;30(4):295–301. 92.
- Martinotti G, Orsolini L, Fornaro M, Vecchiotti R, De Berardis D, Iasevoli F, et al. Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. *Expert Opinion on Investigational Drugs.* 2016 Jun 2;25(6):719–28.

93.

Metzler AI, Robertson CE. Visual Snow Syndrome: Proposed Criteria, Clinical Implications, and Pathophysiology. *Curr Neurol Neurosci Rep*. 2018 Aug;18(8):52.

94.

Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. *Mycological Research*. 2003 Feb;107(2):131–46.

95.

Morehead DB. Exacerbation of Hallucinogen-Persisting Perception Disorder With Risperidone: *Journal of Clinical Psychopharmacology*. 1997 Aug;17(4):327–8.

96.

Pelak VS. The Visual Snow Conference: May 5, 2018, University of California San Francisco. *Journal of Neuro-Ophthalmology*. 2018 Sep;38(3):e17–8.

97.

Puledda F, Schankin C, Digre K, Goadsby PJ. Visual snow syndrome: what we know so far. *Current Opinion in Neurology*. 2018 Feb;31(1):52–8.

98.

Rastogi RG, VanderPluym J, Lewis KS. Migrainous Aura, Visual Snow, and “Alice in Wonderland” Syndrome in Childhood. *Seminars in Pediatric Neurology*. 2016 Feb;23(1):14–7.

99.

Robbins MS. Comment: Time for neurologists to see visual snow. *Neurology*. 2019 Jul 23;93(4):153–153.

100.

Rosenthal SH. PERSISTENT HALLUCINOSIS FOLLOWING REPEATED ADMINISTRATION OF HALLUCINOGENIC DRUGS. *AJP*. 1964 Sep;121(3):238–44.

101.

Sanders-Bush E, Burris KD, Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. *J Pharmacol Exp Ther*. 1988 Sep;246(3):924–8.

102.

Santacroce R, Corazza O, Martinotti G, Bersani FS, Valeriani G, Di Giannantonio M. Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products: PSYCLONES: TWO NEW PRODUCTS FOR THE DRUG MARKET. *Hum Psychopharmacol Clin Exp*. 2015 Jul;30(4):265–71.

103.

Santos-Bueso E, Muñoz-Hernández AM, Avalos-Franco N, García-Sáenz S, Sáenz-Francés F, Porta-Etessam J. Nieve visual en un paciente pediátrico. *Archivos de la Sociedad Española de Oftalmología*. 2017 Dec;92(12):602–4.

104.

Santos-Bueso E, Sastre-Ibáñez M, Sáenz-Francés F, Porta-Etessam J, García-Sánchez J. Nieve visual. ¿Del síntoma al síndrome? *Archivos de la Sociedad Española de Oftalmología*. 2015 Jan;90(1):51–2.

105.

Sastre-Ibáñez M, Santos-Bueso E, Porta-Etessam J, García-Feijoo J. Visual snow: Report of three cases. *Journal Français d’Ophtalmologie*. 2015 Sep;38(7):e157–8.

106.

Schankin CJ, Puledda F, Goadsby PJ. Visual snow syndrome: is it normal or a disorder – and what to do with patients? *Euro J of Neurology*. 2020 Dec;27(12):2393–5.

107.

Schankin CJ, Goadsby PJ. Visual Snow—Persistent Positive Visual Phenomenon Distinct from Migraine Aura. *Curr Pain Headache Rep*. 2015 Jun;19(6):23.

108.

Schankin CJ, Maniyar FH, Sprenger T, Chou DE, Eller M, Goadsby PJ. The Relation Between Migraine, Typical Migraine Aura and “Visual Snow.” Headache: *The Journal of Head and Face Pain*. 2014 Jun;54(6):957–66.

109.

Schatten H, Eter N, Mihailovic N. „Visual snow“ bei „Hallucinogen Persisting Perception Disorder“. *Ophthalmologe*. 2020 Nov;117(11):1112–5.

110.

- Schifano F, Deluca P, Agosti L, Martinotti G, Corkery JM, The Psychonaut 2002 Research Group. New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic'). *J Psychopharmacol*. 2005 Nov;19(6):675–9. 111.
- Schwitzer T, Schwan R, Angioi-Duprez K, Ingster-Moati I, Lalanne L, Giersch A, et al. The cannabinoid system and visual processing: A review on experimental findings and clinical presumptions. *European Neuropsychopharmacology*. 2015 Jan;25(1):100–12. 112.
- Simpson JC, Goadsby PJ, Prabhakar P. Positive Persistent Visual Symptoms (Visual Snow) Presenting as a Migraine Variant in a 12-Year-Old Girl. *Pediatric Neurology*. 2013 Nov;49(5):361–3. 113.
- Skryabin VY, Vinnikova M, Nenastieva A, Alekseyuk V. Hallucinogen persisting perception disorder: A literature review and three case reports. *Journal of Addictive Diseases*. 2018 Oct 2;37(3–4):268–78. 114.
- Solly EJ, Clough M, McKendrick AM, Foletta P, White OB, Fielding J. Ocular motor measures of visual processing changes in visual snow syndrome. *Neurology*. 2020 Sep 29;95(13):e1784–91. 115.
- Subramanian N, Doran M. Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report. *Ir j psychol Med*. 2014 Mar;31(1):47–9. 116.
- Tegetmeyer H. Das Visual-Snow-Syndrom: Symptome und ophthalmologische Befunde. *Klin Monatsbl Augenheilkd*. 2016 Aug 10;234(05):713–8. 117.
- Unal-Cevik I, Yildiz FG. Visual Snow in Migraine With Aura: Further Characterization by Brain Imaging, Electrophysiology, and Treatment - Case Report. *Headache: The Journal of Head and Face Pain*. 2015 Nov;55(10):1436–41. 118.

- Unal-Cevik I. Can We Speak of Lack of Habituation in Visual Snow? A Response. *Headache*. 2016 Oct;56(9):1519–1519. 119.
- Viana M, Puledda F, Goadsby PJ. Visual snow syndrome: a comparison between an Italian and British population. *Eur J Neurol*. 2020 Oct;27(10):2099–101. 120.
- Vroegop MP, van Dongen RTM, Vantroyen B, Kramers C. [Ketamine as a party drug]. *Ned Tijdschr Geneeskd*. 2007 Sep 15;151(37):2039–42. 121.
- White OB, Clough M, McKendrick AM, Fielding J. Visual Snow: Visual Misperception. *Journal of Neuro-Ophthalmology*. 2018 Dec;38(4):514–21. 122.
- Wood H. Shedding new light on visual snow syndrome. *Nat Rev Neurol*. 2020 Apr;16(4):183–183. 123.
- Yildiz FG, Turkyilmaz U, Unal-Cevik I. The Clinical Characteristics and Neurophysiological Assessments of the Occipital Cortex in Visual Snow Syndrome With or Without Migraine. *Headache: The Journal of Head and Face Pain*. 2019 Apr;59(4):484–94. 124.
- Young CR. Sertraline Treatment of Hallucinogen Persisting Perception Disorder. *J Clin Psychiatry*. 1997 Feb 15;58(2):85. 125.
- Zambrowski O, Ingster-Moati I, Vignal-Clermont C, Robert MP. Le phénomène de neige visuelle. *Journal Français d'Ophtalmologie*. 2014 Nov;37(9):722–7. 126.
- Ziaee V, Akbari Hamed E, Hoshmand A, Amini H, Kebriaeizadeh A, Saman K. Side effects of dextromethorphan abuse, a case series. *Addictive Behaviors*. 2005 Sep;30(8):1607–13. 127.

Zobor D, Strasser T, Zobor G, Schober F, Messias A, Strauss O, et al. Ophthalmological assessment of cannabis-induced persisting perception disorder: Is there a direct retinal effect? *Doc Ophthalmol.* 2015 Apr;130(2):121–30.